These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 22125159)
21. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Folgori A; Capone S; Ruggeri L; Meola A; Sporeno E; Ercole BB; Pezzanera M; Tafi R; Arcuri M; Fattori E; Lahm A; Luzzago A; Vitelli A; Colloca S; Cortese R; Nicosia A Nat Med; 2006 Feb; 12(2):190-7. PubMed ID: 16462801 [TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus strategies to evade the specific-T cell response: a possible mission favoring its persistence. Quarleri JF; Oubiña JR Ann Hepatol; 2016; 15(1):17-26. PubMed ID: 26626636 [TBL] [Abstract][Full Text] [Related]
23. Intrahepatic and circulating HLA class II-restricted, hepatitis C virus-specific T cells: functional characterization in patients with chronic hepatitis C. Penna A; Missale G; Lamonaca V; Pilli M; Mori C; Zanelli P; Cavalli A; Elia G; Ferrari C Hepatology; 2002 May; 35(5):1225-36. PubMed ID: 11981773 [TBL] [Abstract][Full Text] [Related]
24. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. Thimme R; Binder M; Bartenschlager R FEMS Microbiol Rev; 2012 May; 36(3):663-83. PubMed ID: 22142141 [TBL] [Abstract][Full Text] [Related]
25. Subversion of immune responses by hepatitis C virus: immunomodulatory strategies beyond evasion? Hahn YS Curr Opin Immunol; 2003 Aug; 15(4):443-9. PubMed ID: 12900277 [TBL] [Abstract][Full Text] [Related]
26. Adaptive immune responses in acute and chronic hepatitis C virus infection. Bowen DG; Walker CM Nature; 2005 Aug; 436(7053):946-52. PubMed ID: 16107834 [TBL] [Abstract][Full Text] [Related]
27. Upregulation of soluble and membrane-bound human leukocyte antigen G expression is primarily observed in the milder histopathological stages of chronic hepatitis C virus infection. de Oliveira Crispim JC; Silva TG; Souto FJ; Souza FF; Bassi CL; Soares CP; Zucoloto S; Moreau P; Martinelli Ade L; Donadi EA Hum Immunol; 2012 Mar; 73(3):258-62. PubMed ID: 22178697 [TBL] [Abstract][Full Text] [Related]
28. Molecular mechanisms of hepatocarcinogenesis in chronic hepatitis C virus infection. Yamashita T; Honda M; Kaneko S J Gastroenterol Hepatol; 2011 Jun; 26(6):960-4. PubMed ID: 21443660 [TBL] [Abstract][Full Text] [Related]
29. Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. Large MK; Kittlesen DJ; Hahn YS J Immunol; 1999 Jan; 162(2):931-8. PubMed ID: 9916717 [TBL] [Abstract][Full Text] [Related]
30. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence. Hiroishi K; Ito T; Imawari M J Gastroenterol Hepatol; 2008 Oct; 23(10):1473-82. PubMed ID: 18761560 [TBL] [Abstract][Full Text] [Related]
31. Hepatitis C virus and the immune system: a concise review. Gremion C; Cerny A Rev Med Virol; 2005; 15(4):235-68. PubMed ID: 15782389 [TBL] [Abstract][Full Text] [Related]
32. Hepatitis C virus (HCV): a review of immunological aspects. Irshad M; Khushboo I; Singh S; Singh S Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353 [TBL] [Abstract][Full Text] [Related]
33. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525 [TBL] [Abstract][Full Text] [Related]
34. Positive selection of cytotoxic T lymphocyte escape variants during acute hepatitis C virus infection. Guglietta S; Garbuglia AR; Pacciani V; Scottà C; Perrone MP; Laurenti L; Spada E; Mele A; Capobianchi MR; Taliani G; Folgori A; Vitelli A; Ruggeri L; Nicosia A; Piccolella E; Del Porto P Eur J Immunol; 2005 Sep; 35(9):2627-37. PubMed ID: 16114108 [TBL] [Abstract][Full Text] [Related]
35. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice. Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486 [TBL] [Abstract][Full Text] [Related]
37. Characterization of novel HLA-DR11-restricted HCV epitopes reveals both qualitative and quantitative differences in HCV-specific CD4+ T cell responses in chronically infected and non-viremic patients. Godkin A; Jeanguet N; Thursz M; Openshaw P; Thomas H Eur J Immunol; 2001 May; 31(5):1438-46. PubMed ID: 11465100 [TBL] [Abstract][Full Text] [Related]
38. Evaluation of hepatitis C virus protein epitopes for vaccine development. Koshy R; Inchauspé G Trends Biotechnol; 1996 Oct; 14(10):364-9. PubMed ID: 8987634 [TBL] [Abstract][Full Text] [Related]
39. [The role of the virus specific T-cell response in acute and chronic HBV and HCV infection]. Panther E; Spangenberg HC; Neumann-Haefelin C; Rösler K; Blum HE; von Weizsäcker F; Thimme R Z Gastroenterol; 2004 Jan; 42(1):39-46. PubMed ID: 14997402 [TBL] [Abstract][Full Text] [Related]
40. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Christie JM; Chapel H; Chapman RW; Rosenberg WM Hepatology; 1999 Oct; 30(4):1037-44. PubMed ID: 10498657 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]